Data capture is no longer the bottleneck, and whether the lag between a signal and a decision shrinks depends on signal design, AI governance, and vendor orchestration.
|Webcasts|March 12, 2020
Virtual, Decentralized, Site-less Trials… What Does it All Mean?
Author(s)Oracle Health Sciences
Patient-facing digital technologies are playing an increasingly important role in clinical trials, to the point where including virtual components in trials has become mainstream. Join Kathy Vandebelt, Global Head of Clinical Innovation at Oracle Health Sciences to discuss where the industry stands on terms like "virtual" or "decentralized" trials, what are the benefits and challenges, and what does the future hold for all of us involved. Live: Thursday, Mar. 12, 2020 at 11am EDT | 8am PDT | 3pm GMT | 4pm CET On demand available after airing until Mar. 12, 2021. Register free
Register free:
Event Overview:
Patient-facing digital technologies are playing an increasingly important role in clinical trials, to the point where including virtual components in trials has become mainstream. But terms like remote, site-less, hybrid, and decentralized trials have added ambiguity and confusion to this new virtual ecosystem. Where exactly does the industry stand on terms like "virtual" or "decentralized" trials?
Whatever the term may be, early planning and implementation stages to protect the integrity of the data will be key to success. Standardization, compliance and regulatory acceptance plays a large role in the development and use of new innovation in clinical trials as well. Above all, it is crucial to protect the safety of the patient.
In collaboration with CNS Summit, Oracle Health Sciences recently met with industry stakeholders to understand the value realized from the decentralized trial approach. In a focus group setting, participants pooled their experience and knowledge to examine the benefits, the challenges and the pace of adoption of various decentralized approaches.
Let’s explore additional aspects of this new frontier, to gain full knowledge of its potential, and what the future holds for all of us involved.
Key Learning Objectives:
Join this webcast to better understand:
How your peers define "decentralized" or "virtual" trials
What are the benefits and challenges of decentralized trials?
What does the future hold for decentralized trials?
Speakers: Kathy Vandebelt, Global Head of Clinical Innovation, Oracle Health Sciences
Vishaal Mehra, CEO & Medical Director, Artemis
Time and date: Thursday, Mar. 12, 2020 at 11am EDT | 8am PDT | 3pm GMT | 4pm CET
On demand available after airing until Mar. 12, 2021.
Sponsor: Oracle Health Sciences
Register free:
Related to this article
In this Q&A, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, discusses what changes when AI is embedded across protocol strategy, data infrastructure, and workflow tools at once, where governance frameworks tend to fall short, and why CROs must orchestrate AI ecosystems rather than simply aggregate them.
In today’s ACT Brief, we examine what policy changes would help community and rural institutions join research, how Walmart is expanding clinical trial centers into three more states, and how FDA approved Ilumya for adults with active psoriatic arthritis.
The planned sites in Livonia, Las Vegas, and San Antonio would expand a partnership that places clinical research and health screenings inside Walmart stores.
In this video interview, Kent Thoelke, CEO of Paradigm Health, calls for safe harbor protections, CMS reimbursement safeguards, and funding mechanisms modeled on EHR meaningful use to help community and rural institutions participate in research on par with academic centers.
In today’s ACT Brief, we examine why community and rural patients lack access to research as a care option, what makes AI assistants trustworthy in regulated trials, and how FDA draft guidance could let gene editing therapies cover patient-specific variants.
In this Q&A, E.K. Koh, chief product officer at Suvoda, discusses what separates a trustworthy AI assistant from one that adds risk, why curated clinical knowledge matters more than general-purpose flexibility, and what safeguards must be in place when assistants move from answering questions to taking actions in clinical trial systems.
In this video interview, Kent Thoelke, CEO of Paradigm Health, explains why patients in community and rural settings too often lack access to clinical research as a care option, and how closing that gap could improve outcomes and lower long-term costs.
Trending on Applied Clinical Trials Online
1
Building AI Assistants Clinical Trial Teams Can Trust: Q&A with E.K. Koh, Suvoda
2
What Needs to Happen Beyond the Clinical Trial Modernization Act
3
From Signal to Action: Why Faster Trial Data Isn’t Producing Faster Decisions
4
Walmart and Care Access Plan Three More Clinical Trial Centers in Michigan, Nevada, and Texas
5